Centuple Global Financial Results

For FY Latest, Rubra Medicaments recorded Net Sales of ₹- crores.This figure helps in determining the company’s true revenue after deducting discounts, returns, and allowances from Gross sales.

The Operating Profit of Rubra Medicaments for FY Latest is ₹- crores. With this amount, one can assess the profits derived from the company’s core (or primary) operations, excluding interest and taxes.

In FY Latest, Rubra Medicaments posted a Profit Before Tax of ₹- croresIt helps to understand whether a company is efficient enough to manage its costs and generate income before eliminating taxes.

Rubra Medicaments recorded a Net Profit of ₹- crores in FY Latest. It is a key indicator of profitability as it gives a more accurate picture of a company’s financial health by considering all costs associated with the business.

The Face Value of Rubra Medicaments shares is -.It indicates the initial capital raised by the company by issuing shares. Face value can determine a stocks current market value at the time of dividends, bonuses, or stock splits.

In FY Latest, the PAT Margin of Rubra Medicaments is - %. This metric provides insights into the company's efficiency in generating profits after paying taxes.

Open a Demat Account with Anand Rathi using the following steps:

1. Enter your basic details in the form.
2. Upload ID proof, PAN card, and bank details.
3. Complete eKYC online.
4. Start investing in Rubra Medicaments using our TradeMobi App or Web Trading Platform.